These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28011272)

  • 1. Resolution of Hydronephrosis in a Patient With Mucopolysaccharidosis Type II With Enzyme Replacement Therapy.
    Nishiyama K; Imai T; Ohkubo K; Sanefuji M; Takada H
    Urology; 2017 Mar; 101():163-165. PubMed ID: 28011272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hunter syndrome follow-up after 1 year of enzyme-replacement therapy.
    Puiu M; Chirita-Emandi A; Dumitriu S; Arghirescu S
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23307460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation.
    Jacques CE; Donida B; Mescka CP; Rodrigues DG; Marchetti DP; Bitencourt FH; Burin MG; de Souza CF; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2016 Sep; 1862(9):1608-16. PubMed ID: 27251652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy.
    Filippon L; Wayhs CA; Atik DM; Manfredini V; Herber S; Carvalho CG; Schwartz IV; Giugliani R; Vargas CR
    Mutat Res; 2011 Apr; 721(2):206-10. PubMed ID: 21334454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses.
    Jones SA; Marsden D; Koutsoukos T; Sniadecki J; Tylee K; Phillippo S; Kakkis E
    Mol Genet Metab; 2020 Aug; 130(4):255-261. PubMed ID: 32563631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome).
    Papadia F; Lozupone MS; Gaeta A; Capodiferro D; Lacalendola G
    Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):253-8. PubMed ID: 21528770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy.
    Filippon L; Vanzin CS; Biancini GB; Pereira IN; Manfredini V; Sitta A; Peralba Mdo C; Schwartz IV; Giugliani R; Vargas CR
    Mol Genet Metab; 2011 Jun; 103(2):121-7. PubMed ID: 21420339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience.
    Ceravolo F; Mascaro I; Sestito S; Pascale E; Lauricella A; Dizione E; Concolino D
    Ital J Pediatr; 2013 Sep; 39():53. PubMed ID: 24011228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Early enzyme replacement therapy - hope for patients with mucopolysaccharidosis Type II].
    Orchel-Szastak K; Ptak K; Hrnciar K; Pilch B; Kania U; Bik-Multanowski M
    Pediatr Endocrinol Diabetes Metab; 2017; 23(2):111-116. PubMed ID: 29073295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
    Beck M
    Curr Pharm Biotechnol; 2011 Jun; 12(6):861-6. PubMed ID: 21235446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.
    Hong J; Cheng YS; Yang S; Swaroop M; Xu M; Beers J; Zou J; Huang W; Marugan JJ; Cai X; Zheng W
    Exp Cell Res; 2022 Mar; 412(1):113007. PubMed ID: 34990619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
    Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
    Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
    Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
    Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
    Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
    Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
    Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
    Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
    Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
    Kim S; Whitley CB; Jarnes Utz JR
    Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation.
    Lee JH; Choe YH; Kim SJ; Paik KH; Jin DK
    Yonsei Med J; 2011 Mar; 52(2):263-7. PubMed ID: 21319344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.